Advocacy intelligence hub — real-time data for patient organizations
Tafinlar(r) Capsules a nd Mekinist(r) Tablets: FDA approved
MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Browse all Cortical dysgenesis with pontocerebellar hypoplasia due to TUBB3 mutation news →
View all Cortical dysgenesis with pontocerebellar hypoplasia due to TUBB3 mutation specialists →